Lisa Demeter
| Title | Professor Emeritus |
|---|
| Institution | School of Medicine and Dentistry |
|---|
| Department | Medicine |
|---|
| Address | University of Rochester Medical Center
School of Medicine and Dentistry
601 Elmwood Ave, Box 689
Rochester NY 14642
|
|---|
|
|
|
| 1984 |
|
| Alpha Omega Alpha | | 1984 |
|
| Bryce Collier Prize | | 1984 |
|
| Janet M. Glasgow Memorial Achievement Citation, awarded by the AMWA | | 1984 |
|
| Rudolph Angell Award | | 1984 |
|
| Doctor of Medicine, awarded with honor, University of Rochester (given to 3 students in the graduating class) | | 1997 |
|
| John Carey Junior Investigator Award, from the NIH-sponsored Adult AIDS Clinical Trials Group (given to one junior investigator per year) |
-
Connick E, Bosch RJ, Aga E, Schlichtemeier R, Demeter LM, Volberding P. Augmented HIV-specific interferon-gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infection. J Acquir Immune Defic Syndr. 2011 Sep 1; 58(1):1-8.
-
Wang J, Zhang G, Bambara RA, Li D, Liang H, Wu H, Smith HM, Lowe NR, Demeter LM, Dykes C. Nonnucleoside reverse transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages of infection. J Virol. 2011 Oct; 85(20):10861-73.
-
Albrecht M, Mukherjee AL, Tierney C, Morse GD, Dykes C, Klingman KL, Demeter LM. A randomized clinical trial evaluating therapeutic drug monitoring (TDM) for protease inhibitor-based regimens in antiretroviral-experienced HIV-infected individuals: week 48 results of the A5146 study. HIV Clin Trials. 2011 Jul-Aug; 12(4):201-14.
-
Piekna-Przybylska D, Dykes C, Demeter LM, Bambara RA. Sequences in the U3 region of human immunodeficiency virus 1 improve efficiency of minus strand transfer in infected cells. Virology. 2011 Feb 20; 410(2):368-74.
-
Hammer SM, Ribaudo H, Bassett R, Mellors JW, Demeter LM, Coombs RW, Currier J, Morse GD, Gerber JG, Martinez AI, Spreen W, Fischl MA, Squires KE. A randomized, placebo-controlled trial of abacavir intensification in HIV-1-infected adults with virologic suppression on a protease inhibitor-containing regimen. HIV Clin Trials. 2010 Nov-Dec; 11(6):312-24.
-
Dykes C, Wu H, Sims M, Holden-Wiltse J, Demeter LM. Human immunodeficiency virus type 1 protease inhibitor drug-resistant mutants give discordant results when compared in single-cycle and multiple-cycle fitness assays. J Clin Microbiol. 2010 Nov; 48(11):4035-43.
-
Dykes C, Mukherjee AL, Bosch RJ, Connick E, Volberding PA, Demeter LM. Prevalence of primary resistance at baseline in acutely and recently infected subjects enrolled in AIDS clinical trials group protocol 371. J Acquir Immune Defic Syndr. 2010 Sep; 55(1):132-4.
-
von Wyl V, Ehteshami M, Demeter LM, Bürgisser P, Nijhuis M, Symons J, Yerly S, Böni J, Klimkait T, Schuurman R, Ledergerber B, Götte M, Günthard HF. HIV-1 reverse transcriptase connection domain mutations: dynamics of emergence and implications for success of combination antiretroviral therapy. Clin Infect Dis. 2010 Sep 1; 51(5):620-8.
-
DiFrancesco R, Rosenkranz S, Mukherjee AL, Demeter LM, Jiang H, DiCenzo R, Dykes C, Rinehart A, Albrecht M, Morse GD. Quality assessment for therapeutic drug monitoring in AIDS Clinical Trials Group (ACTG 5146): a multicenter clinical trial. Ther Drug Monit. 2010 Aug; 32(4):458-66.
-
Wang J, Bambara RA, Demeter LM, Dykes C. Reduced fitness in cell culture of HIV-1 with nonnucleoside reverse transcriptase inhibitor-resistant mutations correlates with relative levels of reverse transcriptase content and RNase H activity in virions. J Virol. 2010 Sep; 84(18):9377-89.
-
Ma J, Dykes C, Wu T, Huang Y, Demeter L, Wu H. vFitness: a web-based computing tool for improving estimation of in vitro HIV-1 fitness experiments. BMC Bioinformatics. 2010; 11:261.
-
Wang J, Liang H, Bacheler L, Wu H, Deriziotis K, Demeter LM, Dykes C. The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations. Virology. 2010 Jul 5; 402(2):228-37.
-
von Wyl V, Ehteshami M, Symons J, Bürgisser P, Nijhuis M, Demeter LM, Yerly S, Böni J, Klimkait T, Schuurman R, Ledergerber B, Götte M, Günthard HF. Epidemiological and biological evidence for a compensatory effect of connection domain mutation N348I on M184V in HIV-1 reverse transcriptase. J Infect Dis. 2010 Apr 1; 201(7):1054-62.
-
Gandhi RT, Bosch RJ, Aga E, Albrecht M, Demeter LM, Dykes C, Bastow B, Para M, Lai J, Siliciano RF, Siliciano JD, Eron JJ. No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. J Infect Dis. 2010 Jan 15; 201(2):293-6.
-
Volberding P, Demeter L, Bosch RJ, Aga E, Pettinelli C, Hirsch M, Vogler M, Martinez A, Little S, Connick E. Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS. 2009 Sep 24; 23(15):1987-95.
-
Demeter LM, Jiang H, Mukherjee AL, Morse GD, DiFrancesco R, DiCenzo R, Dykes C, Sista P, Bacheler L, Klingman K, Rinehart A, Albrecht M. A randomized trial of therapeutic drug monitoring of protease inhibitors in antiretroviral-experienced, HIV-1-infected patients. AIDS. 2009 Jan 28; 23(3):357-68.
-
Miao H, Dykes C, Demeter LM, Cavenaugh J, Park SY, Perelson AS, Wu H. Modeling and estimation of kinetic parameters and replicative fitness of HIV-1 from flow-cytometry-based growth competition experiments. Bull Math Biol. 2008 Aug; 70(6):1749-71.
-
Miao H, Dykes C, Demeter LM, Wu H. Differential equation modeling of HIV viral fitness experiments: model identification, model selection, and multimodel inference. Biometrics. 2009 Mar; 65(1):292-300.
-
Demeter LM, DeGruttola V, Lustgarten S, Bettendorf D, Fischl M, Eshleman S, Spreen W, Nguyen BY, Koval CE, Eron JJ, Hammer S, Squires K. Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience. HIV Clin Trials. 2008 Jan-Feb; 9(1):11-25.
-
Demeter LM, Mukherjee AL, DiFrancesco R, Jiang H, DiCenzo R, Bastow B, Rinehart AR, Morse GD, Albrecht M. The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patients. HIV Clin Trials. 2008 Jan-Feb; 9(1):61-72.
-
Dykes C, Demeter LM. Clinical significance of human immunodeficiency virus type 1 replication fitness. Clin Microbiol Rev. 2007 Oct; 20(4):550-78.
-
Fischl MA, Collier AC, Mukherjee AL, Feinberg JE, Demeter LM, Tebas P, Giuliano M, Dehlinger M, Garren K, Brizz B, Bassett R. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen. AIDS. 2007 Jan 30; 21(3):325-33.
-
Fiscus SA, Cheng B, Crowe SM, Demeter L, Jennings C, Miller V, Respess R, Stevens W. HIV-1 viral load assays for resource-limited settings. PLoS Med. 2006 Oct; 3(10):e417.
-
Domaoal RA, Bambara RA, Demeter LM. HIV-1 reverse transcriptase mutants resistant to nonnucleoside reverse transcriptase inhibitors do not adversely affect DNA synthesis: pre-steady-state and steady-state kinetic studies. J Acquir Immune Defic Syndr. 2006 Aug 1; 42(4):405-11.
-
Luque AE, Jabeen M, Messing S, Lane CA, Demeter LM, Rose RC, Reichman RC. Prevalence of human papillomavirus genotypes and related abnormalities of cervical cytological results among HIV-1-infected women in Rochester, New York. J Infect Dis. 2006 Aug 15; 194(4):428-34.
-
Koval CE, Dykes C, Wang J, Demeter LM. Relative replication fitness of efavirenz-resistant mutants of HIV-1: correlation with frequency during clinical therapy and evidence of compensation for the reduced fitness of K103N + L100I by the nucleoside resistance mutation L74V. Virology. 2006 Sep 15; 353(1):184-92.
-
Dykes C, Wang J, Jin X, Planelles V, An DS, Tallo A, Huang Y, Wu H, Demeter LM. Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture. J Clin Microbiol. 2006 Jun; 44(6):1930-43.
-
Wu H, Huang Y, Dykes C, Liu D, Ma J, Perelson AS, Demeter LM. Modeling and estimation of replication fitness of human immunodeficiency virus type 1 in vitro experiments by using a growth competition assay. J Virol. 2006 Mar; 80(5):2380-9.
-
Wang J, Dykes C, Domaoal RA, Koval CE, Bambara RA, Demeter LM. The HIV-1 reverse transcriptase mutants G190S and G190A, which confer resistance to non-nucleoside reverse transcriptase inhibitors, demonstrate reductions in RNase H activity and DNA synthesis from tRNA(Lys, 3) that correlate with reductions in replication efficiency. Virology. 2006 May 10; 348(2):462-74.
-
Snyder-Cappione JE, Divekar AA, Maupin GM, Jin X, Demeter LM, Mosmann TR. HIV-specific cytotoxic cell frequencies measured directly ex vivo by the Lysispot assay can be higher or lower than the frequencies of IFN-gamma-secreting cells: anti-HIV cytotoxicity is not generally impaired relative to other chronic virus responses. J Immunol. 2006 Feb 15; 176(4):2662-8.
-
Slish JC, Catanzaro LM, Ma Q, Okusanya OO, Demeter L, Albrecht M, Morse GD. Update on the pharmacokinetic aspects of antiretroviral agents: implications in therapeutic drug monitoring. Curr Pharm Des. 2006; 12(9):1129-45.
-
Johnson VA, Brun-Vézinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD. Update of the drug resistance mutations in HIV-1: 2004. Top HIV Med. 2004 Oct-Nov; 12(4):119-24.
-
Domaoal RA, Demeter LM. Structural and biochemical effects of human immunodeficiency virus mutants resistant to non-nucleoside reverse transcriptase inhibitors. Int J Biochem Cell Biol. 2004 Sep; 36(9):1735-51.
-
Dykes C, Balakrishnan M, Planelles V, Zhu Y, Bambara RA, Demeter LM. Identification of a preferred region for recombination and mutation in HIV-1 gag. Virology. 2004 Sep 1; 326(2):262-79.
-
Demeter LM, Ribaudo HJ, Erice A, Eshleman SH, Hammer SM, Hellmann NS, Fischl MA. HIV-1 drug resistance in subjects with advanced HIV-1 infection in whom antiretroviral combination therapy is failing: a substudy of AIDS Clinical Trials Group Protocol 388. Clin Infect Dis. 2004 Aug 15; 39(4):552-8.
-
Jackson JB, Piwowar-Manning E, Johnson-Lewis L, Bassett R, Demeter LM, Brambilla D. Comparison of versions 1.0 AND 1.5 of the UltraSensitive AMPLICOR HIV-1 MONITOR test for subjects with low viral load. J Clin Microbiol. 2004 Jun; 42(6):2774-6.
-
Dykes C, Najjar J, Bosch RJ, Wantman M, Furtado M, Hart S, Hammer SM, Demeter LM. Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine. J Infect Dis. 2004 Mar 15; 189(6):1091-6.
-
Hammer SM, Bassett R, Squires KE, Fischl MA, Demeter LM, Currier JS, Mellors JW, Morse GD, Eron JJ, Santana JL, DeGruttola V. A randomized trial of nelfinavir and abacavir in combination with efavirenz and adefovir dipivoxil in HIV-1-infected persons with virological failure receiving indinavir. Antivir Ther. 2003 Dec; 8(6):507-18.
-
Johnson VA, Brun-Vézinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD. Drug resistance mutations in HIV-1. Top HIV Med. 2003 Nov-Dec; 11(6):215-21.
-
Chadha KC, Schwartz SA, Nair MP, Demeter LR, Hewitt RG. Serum interferon inhibitor declines in patients with HIV-1 infection after a change in antiretroviral therapy. Immunol Invest. 2003 Nov; 32(4):299-312.
-
Fischl MA, Ribaudo HJ, Collier AC, Erice A, Giuliano M, Dehlinger M, Eron JJ, Saag MS, Hammer SM, Vella S, Morse GD, Feinberg JE, Demeter LM, Eshleman SH. A randomized trial of 2 different 4-drug antiretroviral regimens versus a 3-drug regimen, in advanced human immunodeficiency virus disease. J Infect Dis. 2003 Sep 1; 188(5):625-34.
-
Hirsch MS, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Richman DD. Questions to and answers from the International AIDS Society-USA Resistance Testing Guidelines Panel. Top HIV Med. 2003 Jul-Aug; 11(4):150-4.
-
Hirsch MS, Brun-Vézinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, Demeter LM, Hammer SM, Johnson VA, Loveday C, Mellors JW, Jacobsen DM, Richman DD. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2003 Jul 1; 37(1):113-28.
-
D'Aquila RT, Schapiro JM, Brun-Vézinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD. Drug resistance mutations in HIV-1. Top HIV Med. 2003 May-Jun; 11(3):92-6.
-
Koval CE, Gigliotti F, Nevins D, Demeter LM. Immune reconstitution syndrome after successful treatment of Pneumocystis carinii pneumonia in a man with human immunodeficiency virus type 1 infection. Clin Infect Dis. 2002 Aug 15; 35(4):491-3.
-
Demeter LM, Bosch RJ, Coombs RW, Fiscus S, Bremer J, Johnson VA, Erice A, Jackson JB, Spector SA, Squires KM, Fischl MA, Hughes MD, Hammer SM. Detection of replication-competent human immunodeficiency virus type 1 (HIV-1) in cultures from patients with levels of HIV-1 RNA in plasma suppressed to less than 500 or 50 copies per milliliter. J Clin Microbiol. 2002 Jun; 40(6):2089-94.
-
Demeter LM, Hughes MD, Coombs RW, Jackson JB, Grimes JM, Bosch RJ, Fiscus SA, Spector SA, Squires KE, Fischl MA, Hammer SM. Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320. Ann Intern Med. 2001 Dec 4; 135(11):954-64.
-
Renda MJ, Rosenblatt JD, Klimatcheva E, Demeter LM, Bambara RA, Planelles V. Mutation of the methylated tRNA(Lys)(3) residue A58 disrupts reverse transcription and inhibits replication of human immunodeficiency virus type 1. J Virol. 2001 Oct; 75(20):9671-8.
-
Dykes C, Fox K, Lloyd A, Chiulli M, Morse E, Demeter LM. Impact of clinical reverse transcriptase sequences on the replication capacity of HIV-1 drug-resistant mutants. Virology. 2001 Jul 5; 285(2):193-203.
-
Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA, O'Brien D, Campbell M, White WI, Balsley J, Reichman RC. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis. 2001 May 15; 183(10):1485-93.
-
Archer RH, Wisniewski M, Bambara RA, Demeter LM. The Y181C mutant of HIV-1 reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors alters the size distribution of RNase H cleavages. Biochemistry. 2001 Apr 3; 40(13):4087-95.
-
Haubrich R, Demeter L. International perspectives on antiretroviral resistance. Clinical utility of resistance testing: retrospective and prospective data supporting use and current recommendations. J Acquir Immune Defic Syndr. 2001 Mar 1; 26 Suppl 1:S51-9.
-
Demeter L, Haubrich R. International perspectives on antiretroviral resistance. Phenotypic and genotypic resistance assays: methodology, reliability, and interpretations. J Acquir Immune Defic Syndr. 2001 Mar 1; 26 Suppl 1:S3-9.
-
Archer RH, Dykes C, Gerondelis P, Lloyd A, Fay P, Reichman RC, Bambara RA, Demeter LM. Mutants of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase resistant to nonnucleoside reverse transcriptase inhibitors demonstrate altered rates of RNase H cleavage that correlate with HIV-1 replication fitness in cell culture. J Virol. 2000 Sep; 74(18):8390-401.
-
Dykes C, Mootsikapun P, Dexter A, Berrios L, Chiulli M, Reichman RC, Demeter LM. Analysis of env sequence evolution in human immunodeficiency virus-infected patients receiving therapy with nonnucleoside reverse-transcriptase inhibitors. J Infect Dis. 2000 Jul; 182(1):316-20.
-
Schifitto G, McDermott MP, Evans T, Fitzgerald T, Schwimmer J, Demeter L, Kieburtz K. Autonomic performance and dehydroepiandrosterone sulfate levels in HIV-1-infected individuals: relationship to TH1 and TH2 cytokine profile. Arch Neurol. 2000 Jul; 57(7):1027-32.
-
Hirsch MS, Brun-Vézinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, Loveday C, Mellors JW, Clotet B, Conway B, Demeter LM, Vella S, Jacobsen DM, Richman DD. Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA. 2000 May 10; 283(18):2417-26.
-
Demeter LM, Shafer RW, Meehan PM, Holden-Wiltse J, Fischl MA, Freimuth WW, Para MF, Reichman RC. Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrob Agents Chemother. 2000 Mar; 44(3):794-7.
-
Morse GD, Reichman RC, Fischl MA, Para M, Leedom J, Powderly W, Demeter LM, Resnick L, Bassiakos Y, Timpone J, Cox S, Batts D. Concentration-targeted phase I trials of atevirdine mesylate in patients with HIV infection: dosage requirements and pharmacokinetic studies. The ACTG 187 and 199 study teams. Antiviral Res. 2000 Jan; 45(1):47-58.
-
Friedland GH, Pollard R, Griffith B, Hughes M, Morse G, Bassett R, Freimuth W, Demeter L, Connick E, Nevin T, Hirsch M, Fischl M. Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cells/mm3 (ACTG 261). ACTG 261 Team. J Acquir Immune Defic Syndr. 1999 Aug 1; 21(4):281-92.
-
Gerondelis P, Archer RH, Palaniappan C, Reichman RC, Fay PJ, Bambara RA, Demeter LM. The P236L delavirdine-resistant human immunodeficiency virus type 1 mutant is replication defective and demonstrates alterations in both RNA 5'-end- and DNA 3'-end-directed RNase H activities. J Virol. 1999 Jul; 73(7):5803-13.
-
Schuurman R, Demeter L, Reichelderfer P, Tijnagel J, de Groot T, Boucher C. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. J Clin Microbiol. 1999 Jul; 37(7):2291-6.
-
Para MF, Meehan P, Holden-Wiltse J, Fischl M, Morse G, Shafer R, Demeter LM, Wood K, Nevin T, Virani-Ketter N, Freimuth WW. ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team. Antimicrob Agents Chemother. 1999 Jun; 43(6):1373-8.
-
Luque AE, Demeter LM, Reichman RC. Association of human papillomavirus infection and disease with magnitude of human immunodeficiency virus type 1 (HIV-1) RNA plasma level among women with HIV-1 infection. J Infect Dis. 1999 Jun; 179(6):1405-9.
-
Demeter LM, D'Aquila R, Weislow O, Lorenzo E, Erice A, Fitzgibbon J, Shafer R, Richman D, Howard TM, Zhao Y, Fisher E, Huang D, Mayers D, Sylvester S, Arens M, Sannerud K, Rasheed S, Johnson V, Kuritzkes D, Reichelderfer P, Japour A. Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. ACTG Sequencing Working Group. AIDS Clinical Trials Group. J Virol Methods. 1998 Nov; 75(1):93-104.
-
Demeter LM, Meehan PM, Morse G, Fischl MA, Para M, Powderly W, Leedom J, Holden-Wiltse J, Greisberger C, Wood K, Timpone J, Wathen LK, Nevin T, Resnick L, Batts DH, Reichman RC. Phase I study of atevirdine mesylate (U-87201E) monotherapy in HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Oct 1; 19(2):135-44.
-
Hirsch MS, Conway B, D'Aquila RT, Johnson VA, Brun-Vézinet F, Clotet B, Demeter LM, Hammer SM, Jacobsen DM, Kuritzkes DR, Loveday C, Mellors JW, Vella S, Richman DD. Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA. 1998 Jun 24; 279(24):1984-91.
-
Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM, Currier JS, Eron JJ, Feinberg JE, Balfour HH, Deyton LR, Chodakewitz JA, Fischl MA. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med. 1997 Sep 11; 337(11):725-33.
-
Demeter LM, Meehan PM, Morse G, Gerondelis P, Dexter A, Berrios L, Cox S, Freimuth W, Reichman RC. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Feb 1; 14(2):136-44.
-
Paxton WB, Coombs RW, McElrath MJ, Keefer MC, Hughes J, Sinangil F, Chernoff D, Demeter L, Williams B, Corey L. Longitudinal analysis of quantitative virologic measures in human immunodeficiency virus-infected subjects with > or = 400 CD4 lymphocytes: implications for applying measurements to individual patients. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. J Infect Dis. 1997 Feb; 175(2):247-54.
-
Welles SL, Jackson JB, Yen-Lieberman B, Demeter L, Japour AJ, Smeaton LM, Johnson VA, Kuritzkes DR, D'Aquila RT, Reichelderfer PA, Richman DD, Reichman R, Fischl M, Dolin R, Coombs RW, Kahn JO, McLaren C, Todd J, Kwok S, Crumpacker CS. Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team. J Infect Dis. 1996 Oct; 174(4):696-703.
-
Bonnez W, Oakes D, Choi A, d'Arcy SJ, Pappas PG, Corey L, Stoler MH, Demeter LM, Reichman RC. Therapeutic efficacy and complications of excisional biopsy of condyloma acuminatum. Sex Transm Dis. 1996 Jul-Aug; 23(4):273-6.
-
Demeter LM, Nawaz T, Morse G, Dolin R, Dexter A, Gerondelis P, Reichman RC. Development of zidovudine resistance mutations in patients receiving prolonged didanosine monotherapy. J Infect Dis. 1995 Dec; 172(6):1480-5.
-
Frenkel LM, Wagner LE, Demeter LM, Dewhurst S, Coombs RW, Murante BL, Reichman RC. Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1. Clin Infect Dis. 1995 May; 20(5):1321-6.
-
Reichman RC, Morse GD, Demeter LM, Resnick L, Bassiakos Y, Fischl M, Para M, Powderly W, Leedom J, Greisberger C, et al. Phase I study of atevirdine, a nonnucleoside reverse transcriptase inhibitor, in combination with zidovudine for human immunodeficiency virus type 1 infection. ACTG 199 Study Team. J Infect Dis. 1995 Feb; 171(2):297-304.
-
Demeter LM, Stoler MH, Broker TR, Chow LT. Induction of proliferating cell nuclear antigen in differentiated keratinocytes of human papillomavirus-infected lesions. Hum Pathol. 1994 Apr; 25(4):343-8.
-
Demeter LM, Stoler MH, Bonnez W, Corey L, Pappas P, Strussenberg J, Reichman RC. Penile intraepithelial neoplasia: clinical presentation and an analysis of the physical state of human papillomavirus DNA. J Infect Dis. 1993 Jul; 168(1):38-46.
-
Dollard SC, Wilson JL, Demeter LM, Bonnez W, Reichman RC, Broker TR, Chow LT. Production of human papillomavirus and modulation of the infectious program in epithelial raft cultures. OFF. Genes Dev. 1992 Jul; 6(7):1131-42.
-
Demeter LM, Stoler MH, Sobel ME, Broker TR, Chow LT. Expression of high-affinity laminin receptor mRNA correlates with cell proliferation rather than invasion in human papillomavirus-associated cervical neoplasms. Cancer Res. 1992 Mar 15; 52(6):1561-7.
-
Reichman RC, Oakes D, Bonnez W, Brown D, Mattison HR, Bailey-Farchione A, Stoler MH, Demeter LM, Tyring SK, Miller L, et al. Treatment of condyloma acuminatum with three different interferon-alpha preparations administered parenterally: a double-blind, placebo-controlled trial. J Infect Dis. 1990 Dec; 162(6):1270-6.
|
Demeter's Networks
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|
